IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 26.172
Totale 26.172
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 26.172
Totale 26.172
Salva come PNG Salva come JPEG
Città #
Genova 21.510
Rapallo 2.410
Genoa 2.164
Vado Ligure 49
Bordighera 39
Totale 26.172
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 243
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 178
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 174
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 157
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 151
Pituitary image: pituicytoma. 149
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 149
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 148
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 143
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 143
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 139
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 137
Computed tomography colonography in acromegaly 137
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 136
The pathology of the ulnar nerve in acromegaly. 135
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 135
Rare diseases in clinical endocrinology: A taxonomic classification system 134
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 133
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 133
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 132
Initial staging of lymphoma with octreotide and other receptor imaging agents. 130
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 130
Dopamine receptor expression and function in corticotroph ectopic tumors. 129
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 129
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 128
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 128
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 128
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 127
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 127
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 127
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 126
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 126
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 125
Managing Cushing's disease: The state of the art 124
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 123
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 123
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 122
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 122
Acromegaly is associated with increased cancer risk: A survey in Italy 122
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 121
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 121
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 121
Hormone receptors analysis in idiopathic progressive subglottic stenosis 120
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 120
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 120
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 120
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 119
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 119
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 119
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. 118
Somatostatin receptor expression in thymic tumors. 116
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas 116
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 116
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. 116
Sympathovagal imbalance in acromegalic patients 115
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 115
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 115
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 114
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 114
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 114
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 114
Somatostatin receptor scintigraphy in thoracic diseases 113
Interactions between vitamin D and IGF-I: from physiology to clinical practice 113
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 112
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 111
Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. 111
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 111
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 111
Zebrafish as an innovative model for neuroendocrine tumors 111
Well-differentiated pancreatic tumor/carcinoma: insulinoma. 110
P68 Insulin-like growth factor (IGF) binding protein-3 inhibits IGF-II-stimulated IRS-1/PI-3-kinase activity and cell growth in human non-small cell lung cancer (NSCLC) cell lines 110
Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. 110
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 109
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors 109
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 109
Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. 108
Long-term outcome of low-activity radioiodine administration preceded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. 108
Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. 108
Sonographic depiction of trigger fingers in acromegaly. 108
P87 Effect of exenatide, sitagliptin and vildagliptin on IGF-I in diabetic patients 108
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 107
Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. 107
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 107
In memory of Francesco Maria Minuto. 107
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 107
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 106
Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. 106
A pilot study on nerve ultrasound in acromegaly 106
Trigger Finger, an Early Musculoskeletal Manifestation of Acromegaly 106
Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. 106
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 106
Peptide receptor therapies in neuroendocrine tumors. 105
Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas. 105
Somatostatin receptor ligands in the treatment of acromegaly 105
Effect of growth hormone on cardiac function. 105
Prediction of efficacy of octreotide therapy in patients with acromegaly. 104
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 104
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry 104
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 104
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database 104
Totale 12.166
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.946
article - articoli 78.226
book - libri 0
conference - conferenze 385
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 335
Totale 157.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.525 360 213 417 477 684 740 1.116 521 694 1.236 781 286
2020/20212.680 131 281 314 331 199 191 100 291 201 283 190 168
2021/20223.419 97 221 283 437 90 250 257 734 174 315 163 398
2022/20232.950 328 208 39 269 442 522 23 217 529 26 302 45
2023/20241.648 90 220 39 186 129 283 107 69 100 66 100 259
2024/2025122 122 0 0 0 0 0 0 0 0 0 0 0
Totale 26.658